$NTHISep 17, 2026, 8:54 AM ETAI processed
NTHI redeems Series A preferred for $6M after announcing $15M registered direct
AI Summary
NeOnc (NTHI) redeemed all 6,000 shares of its Series A Convertible Preferred for $6.0M in cash, eliminating a potential discounted conversion and removing that overhang immediately. The move came days after the company announced a $15M registered direct offering that management said was structured to fund the redemption; dilution from the registered direct is delayed/undetermined until that offering closes. Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.
Positives
- Redeemed 6,000 Series A preferred for $6.0M cash, immediately removing potential conversion at a steep discount
- Announced $15M registered direct offering to provide fresh capital (intended to support the redemption)
- Company reports advancing clinical programs (NEO100 topline Phase 2a results and NEO212 Phase 1 completion), which are the intended uses of capital
Negatives
- Registered direct offering terms (price, share/unit count, warrants) and closing are not disclosed, so dilution timing and size are undetermined
- Redemption consumed $6.0M in cash, reducing available liquidity
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: date unknown
Dilution status
delayed
Dilution timing
Dilution status: Delayed